Key Takeaways
- • TA Associates Management LP, a Boston-based private equity firm, is in advanced talks to acquire Advanced Medical Solutions Group PLC for approximately £600 million, or 280 pence per share—representing a significant premium to the stock's closing price of 228 pence on Friday.
- • Advanced Medical Solutions confirmed formal offer-period talks on April 20, 2026, with the bidder granted a standard 28-day window to table formal intentions; an agreed deal could be announced within days according to Sky News reporting.
- • AMS Group delivered strong 2025 financial performance with pretax profit surging 81% to £17.8 million and revenue growing 29% to £228.9 million, bolstering valuation support for the transaction and signaling operational momentum.
- • The AIM-listed surgical dressings company has appreciated 25% over the past 12 months on market consolidation trends, improved governance, and strategic acquisition activity including the Peters Surgical and Connexicon Medical acquisitions.
- • Serious private equity interest reflects sector consolidation dynamics; competing bids from Bridgepoint and Montagu Private Equity have also been reported, indicating robust competition for the asset.
Summary
Advanced Medical Solutions Group PLC, a Cheshire-based surgical dressings manufacturer listed on the AIM exchange, confirmed on April 20, 2026, that it is in formal offer-period talks with TA Associates Management LP regarding a potential acquisition. The Boston-based private equity firm is preparing a bid valuing the company at approximately £600 million, or 280 pence per share—a material premium to AMS's Friday closing price of 228 pence. According to Sky News reporting, an agreed transaction could be announced within days, though sources cautioned that while serious discussions have been underway for some time, deal closure is not guaranteed.
The formal offer period grants TA Associates a standard 28-day window to submit binding proposals, initiating the structured auction process required under UK takeover regulations. Both AMS Group and TA Associates declined to comment to Sky News, limiting publicly available detail on transaction terms and conditions at this stage. The announcement confirms sustained private equity interest in the medical devices sector, with earlier reports indicating exploration of bids by competing firms Bridgepoint (reportedly at £550 million) and Montagu Private Equity, signaling robust competitive tension for the asset.
AMS Group's timing for this transaction comes on the heels of exceptional 2025 financial performance. The company reported pretax profit surging 81% year-over-year to £17.8 million from £9.8 million, while revenue grew 29% to £228.9 million from £177.5 million. Management raised its final dividend to 2.01 pence per share, bringing the total annual dividend to 2.86 pence per share—a 10% increase. The stock has appreciated 25% over the past 12 months, reflecting investor recognition of operational execution and the company's strategic acquisition activity, including the integration of Peters Surgical and Connexicon Medical Limited.
The valuation dynamics underscore private equity appetite for consolidation in specialty medical devices. At 280 pence per share, TA Associates' indicative offer reflects a modest premium to prevailing market prices, pricing in both demonstrated earnings growth and the continued sector consolidation narrative that has attracted multiple bidders. The outcome of this formal offer period will shape the competitive landscape for specialty surgical and wound-care businesses within the medical technology sector.
The formal offer period grants TA Associates a standard 28-day window to submit binding proposals, initiating the structured auction process required under UK takeover regulations. Both AMS Group and TA Associates declined to comment to Sky News, limiting publicly available detail on transaction terms and conditions at this stage. The announcement confirms sustained private equity interest in the medical devices sector, with earlier reports indicating exploration of bids by competing firms Bridgepoint (reportedly at £550 million) and Montagu Private Equity, signaling robust competitive tension for the asset.
AMS Group's timing for this transaction comes on the heels of exceptional 2025 financial performance. The company reported pretax profit surging 81% year-over-year to £17.8 million from £9.8 million, while revenue grew 29% to £228.9 million from £177.5 million. Management raised its final dividend to 2.01 pence per share, bringing the total annual dividend to 2.86 pence per share—a 10% increase. The stock has appreciated 25% over the past 12 months, reflecting investor recognition of operational execution and the company's strategic acquisition activity, including the integration of Peters Surgical and Connexicon Medical Limited.
The valuation dynamics underscore private equity appetite for consolidation in specialty medical devices. At 280 pence per share, TA Associates' indicative offer reflects a modest premium to prevailing market prices, pricing in both demonstrated earnings growth and the continued sector consolidation narrative that has attracted multiple bidders. The outcome of this formal offer period will shape the competitive landscape for specialty surgical and wound-care businesses within the medical technology sector.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.